EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131 I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Benjamin J Lerman iD, Katherine K Matthay iD, Fabienne Hollinger, Catriona Black, Ann A Lazar, Miguel Pampaloni, Steven G DuBois iD, Kieuhoa T Vo

Pediatric Blood & Cancer · 2026-08 · 73 (8)

DOI: 10.1002/1545-5017.70385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 12.05.2026. Verfasst von Benjamin J Lerman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California San Francisco and Benioff Children's Hospitals, San Francisco, California, USA. Hauptthemen laut MEDLINE: Neuroblastoma, 3-Iodobenzylguanidine, Iodine Radioisotopes, Immunotherapy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Alex's Lemonade Stand Centers of Excellence.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

131 I‐metaiodobenzylguanidine ( 131 I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment. However, response rates to 131 I‐MIBG in the anti‐GD2 era are unknown, and the factors associated with response are poorly defined. Procedure We retrospectively quantified objective response rates (ORR) to 131 I‐MIBG and evaluated the association between clinical and molecular features—including receipt of anti‐GD2 immunotherapy—and ORR among participants with R/R NB from 2011 to 2023. Variables with an unadjusted odds ratio [uOR] p < 0.2 in a univariable screen were included in multivariable analysis.

Results

A total of 125 participants with relapsed (60.8%) or refractory (39.2%) NB were included. Fifty‐eight (46.4%) previously received anti‐GD2 antibody therapy. Forty‐seven (37.6%) achieved an objective response to 131 I‐MIBG therapy, 56 had stable disease (SD; 44.8%), and 22 had progressive disease (17.6%). Compared to immunotherapy‐naïve participants (ORR 35.8%), participants who previously received anti‐GD2 therapy (39.7%, uOR 1.18 [0.57–2.4]) and specifically chemoimmunotherapy (37.5%, 0.99 [0.42–2.26]) had similar rates of response to 131 I‐MIBG. Asians compared to Whites (adjusted OR 0.21 [0.05–0.95]), no bone marrow disease (0.17 [0.06–0.50]), and higher Curie score (0.90 [0.83–0.98]) were significantly associated with lower odds of response.

Conclusion

Prior exposure to anti‐GD2 therapy was not associated with differential response to 131 I‐MIBG. ORR in this modern cohort was comparable to that reported in previous studies. Participants with bone marrow disease and a lower Curie score have a significantly higher ORR to 131 I‐MIBG therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroblastoma3-IodobenzylguanidineIodine RadioisotopesImmunotherapyGangliosidesDrug Resistance, NeoplasmHumansFemaleRetrospective StudiesMaleChild, PreschoolInfantChildPrognosisFollow-Up Studies

Stichwörter der Autor:innen

131I‐MIBGmetaiodobenzylguanidineneuroblastomaradiotherapy

Substanzen

3-IodobenzylguanidineIodine RadioisotopesGangliosidesganglioside, GD2Iodine-131

Autor:innen und Institutionen

  • Department of Pediatrics, University of California San Francisco and Benioff Children's Hospitals, San Francisco, California, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
  • Department of Preventive and Restorative Dental Sciences, University of California San Francisco, San Francisco, California, USA.
  • Department of Radiology, University of California San Francisco and Benioff Children's Hospitals, San Francisco, California, USA.
  • Department of Pediatrics, Dana-Farber/Boston Children's Cancer and Blood Disorders Centers, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Benjamin J Lerman, Katherine K Matthay, Steven G DuBois

Förderung

  • NCI NIH HHS
  • Alex's Lemonade Stand Centers of Excellence

Zitieren

APA

Lerman, B. J., Matthay, K. K., Hollinger, F., Black, C., Lazar, A. A., Pampaloni, M., DuBois, S. G., & Vo, K. T. (2026). Clinical and Biological Features of Response in Resistant Neuroblastoma to 131 I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era. Pediatric Blood & Cancer, 73(8). https://doi.org/10.1002/1545-5017.70385

Vancouver

Lerman BJ, Matthay KK, Hollinger F, Black C, Lazar AA, Pampaloni M, et al. Clinical and Biological Features of Response in Resistant Neuroblastoma to 131 I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era. Pediatric Blood & Cancer. 2026;73(8). doi:10.1002/1545-5017.70385

BibTeX
@article{Lerman2026,
  author = {Lerman, Benjamin J and Matthay, Katherine K and Hollinger, Fabienne and Black, Catriona and Lazar, Ann A and Pampaloni, Miguel and DuBois, Steven G and Vo, Kieuhoa T},
  title = {Clinical and Biological Features of Response in Resistant Neuroblastoma to 131 I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {8},
  doi = {10.1002/1545-5017.70385}
}
Kostenlos starten →